An efficient deprotection method for 5′-[O,O-bis(pivaloyloxymethyl)]-(E)-vinylphosphonate containing oligonucleotides
暂无分享,去创建一个
M. Manoharan | K. Charissé | I. R. Babu | M. Maier | Jonathan O’Shea | Christopher S. Theile | Ivan Zlatev | Rajat S Das
[1] K. G. Rajeev,et al. Facile Synthesis, Geometry, and 2'-Substituent-Dependent in Vivo Activity of 5'-(E)- and 5'-(Z)-Vinylphosphonate-Modified siRNA Conjugates. , 2018, Journal of medicinal chemistry.
[2] S. Milstein,et al. Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.
[3] D. Corey,et al. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs , 2017, Nucleic acids research.
[4] K. Ranganna,et al. Therapeutic potential of chemically modified siRNA: Recent trends , 2017, Chemical biology & drug design.
[5] K. G. Rajeev,et al. Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates , 2017, Nucleic acids research.
[6] W. Litchy,et al. Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy , 2017, BMC Neurology.
[7] A. Akinc,et al. Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy , 2017, The New England journal of medicine.
[8] A. Khvorova,et al. 5΄-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo , 2017, Nucleic acids research.
[9] C. Stein,et al. FDA-Approved Oligonucleotide Therapies in 2017. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[10] R. Titze-de-Almeida,et al. The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market , 2017, Pharmaceutical Research.
[11] B. Bettencourt,et al. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 , 2017, The New England journal of medicine.
[12] B. Bettencourt,et al. Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[13] M. Manoharan,et al. siRNA carrying an (E)-vinylphosphonate moiety at the 5΄ end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2 , 2016, Nucleic acids research.
[14] I. MacRae,et al. Structural Analysis of Human Argonaute-2 Bound to a Modified siRNA Guide. , 2016, Journal of the American Chemical Society.
[15] M. Graham,et al. Synergistic effect of phosphorothioate, 5'-vinylphosphonate and GalNAc modifications for enhancing activity of synthetic siRNA. , 2016, Bioorganic & medicinal chemistry letters.
[16] K. G. Rajeev,et al. 5′‐(E)‐Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA–GalNAc Conjugates , 2016, Chembiochem : a European journal of chemical biology.
[17] K. G. Rajeev,et al. 5'-C-Malonyl RNA: Small Interfering RNAs Modified with 5'-Monophosphate Bioisostere Demonstrate Gene Silencing Activity. , 2016, ACS chemical biology.
[18] Wenyu Li,et al. Identification of metabolically stable 5′-phosphate analogs that support single-stranded siRNA activity , 2015, Nucleic acids research.
[19] Amy Chan,et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. , 2014, Journal of the American Chemical Society.
[20] V. Venditto,et al. Photohydrate‐Mediated Reactions of Uridine, 2′‐Deoxyuridine and 2′‐Deoxycytidine with Amines at Near Neutral pH , 2013, Photochemistry and photobiology.
[21] Stanley T. Crooke,et al. Single-Stranded siRNAs Activate RNAi in Animals , 2012, Cell.
[22] James A. Powell,et al. Streamlined process for the chemical synthesis of RNA using 2'-O-thionocarbamate-protected nucleoside phosphoramidites in the solid phase. , 2011, Journal of the American Chemical Society.
[23] P. Hadwiger,et al. Characterization of side reactions during the annealing of small interfering RNAs. , 2011, Analytical biochemistry.
[24] K. G. Rajeev,et al. Utilizing Chemistry to Harness RNA Interference Pathways for Therapeutics: Chemically Modified siRNAs and Antagomirs , 2007 .
[25] Javier Martinez,et al. The human RNA kinase hClp1 is active on 3′ transfer RNA exons and short interfering RNAs , 2007, Nature.
[26] T. Wada,et al. Nitromethane as a scavenger of acrylonitrile in the deprotection of synthetic oligonucleotides , 2005 .
[27] Jim Arnold,et al. Synthesis of High-Quality Antisense Drugs. Addition of Acrylonitrile to Phosphorothioate Oligonucleotides: Adduct Characterization and Avoidance , 2003 .
[28] Leemor Joshua-Tor,et al. Slicer and the argonautes. , 2007, Nature chemical biology.